The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)

RecruitingOBSERVATIONAL
Enrollment

360

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

December 31, 2024

Conditions
Coronary Artery Disease
Interventions
DRUG

Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor

"Patients (180 diabetic patients with CAD that are using SGLT-2 inhibitors and 180 diabetic patients with CAD that are not using SGLT-2 inhibitors) who fulfil the inclusion and exclusion criteria will be recruited from the following sources:~UMMC Cardiology and Diabetes out-patient clinics UMMC Cardiology and Endocrinology in-patients (wards)~During the recruitment, patients will do baseline echocardiography in which includes epicardial adipose tissue and cardiac function. The same procedure will be repeated 6 months post intervention."

Trial Locations (1)

40170

RECRUITING

Institute for Clinical Research, National Institutes of Health, Malaysia, Shah Alam

All Listed Sponsors
collaborator

University of Malaya

OTHER

collaborator

Ministry of Health, Malaysia

OTHER_GOV

lead

Clinical Research Centre, Malaysia

OTHER